Robert Chun-Hao Hsu, MD

medical oncologist

University of Southern California Norris Comprehensive Cancer Center in Los Angeles

Published Articles (1)

Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up

June 24, 2026

KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.